Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.

University Of Pittsburgh Researchers Uncover Mitochondrial Defect Involved With Inherited Cancers

PITTSBURGH, February 3, 2000 — University of Pittsburgh researchers have uncovered a major new concept of how a certain type of tumor develops by linking a specific defect in mitochondria to a type of inherited tumor.

The Pitt scientists, led by Bora E. Baysal, M.D., Ph.D. and Bernie Devlin, Ph.D., Western Psychiatric Institute and Clinic, found that a defective gene on chromosome 11q23, a region previously implicated in the progression of many solid cancerous tumors, causes a hereditary tumor called hereditary paraganglioma. Paraganglioma tumors most commonly occur in the carotid body, a small organ located in the carotid artery in the neck that senses blood oxygen levels. This discovery is important because for the first time it ties a genetic defect in mitochondria (energy producing organelles inside the cell) to tumor development.

Results of the study appear in today’s issue of the journal Science.

The researchers became interested in families with paraganglioma who show a peculiar inheritance pattern, which can be explained by a process called "genomic imprinting."

While the genetic defect is transmitted through both mothers and fathers, tumors develop only when fathers transmit the defect. The researchers found that a gene named succinate-ubiquinone oxido-reductase (SDHD), that codes for an integral part of mitochondrial complex II, was defective in families with paraganglioma. By the researchers’ reasoning, the defect is likely to cause mitochondria to fail to properly sense the oxygen levels in the cell. And, because of the oxygen-sensing defect, the carotid body is chronically stimulated to compensate for the lack of oxygen. This chronic stimulation eventually leads to cellular proliferation and tumor development. Chronic atmospheric hypoxia (reduced oxygen level) was previously linked to the development of paraganglioma tumors in people living at high altitudes.

It is conceivable, argue the researchers, that defective oxygen sensing is a fundamental process for the progression of many common solid cancers. It is well known that lack of oxygen helps the development of more malignant cell types in common solid tumors.

"This finding is important because we know that hypoxia actually helps some common forms of cancer become more hardy," said Dr. Baysal. "Most cells, and most cancer cells, are harmed by low oxygen. Low oxygen normally causes cells to self-destruct. In some cancer cells, however, the mechanism for cell death is turned off. These cells reproduce under the difficult conditions brought on by low oxygen levels. The result is that the tumor cells are more aggressive and more difficult to treat. The stressful environment of hypoxia creates a stronger tumor."

According to Dr. Baysal, some types of chemotherapy and radiation treatments rely on oxygen as a reagent to destroy cancer cells. In a tumor with low oxygen levels, those therapies cannot be as effective.

If the Pitt research team’s hypothesis is correct, this discovery may lead to more effective cancer treatments, and have important implications for other common diseases where hypoxia is involved, like stroke and heart attack. The discovery of the gene may also reveal novel "genomic imprinting" mechanisms to explain why only fathers transmit this tumor, said Dr. Baysal.

The University of Pittsburgh researchers were Robert E. Ferrell, Ph.D.; Joan E. Willett-Brozick, B.S.; Elizabeth C. Lawrence, B.S.; Wendy S. Rubinstein, M.D., Ph.D.; and Eugene N. Myers, M.D. Collaborating researchers involved were David Myssiorek, M.D., Department of Otolaryngology and Communicative Disorders, Long Island Jewish Medical Center; Anne Bosch, B.S.; Andel van der Mey, M.D.; Peter E.M. Taschner, Ph.D.; Peter Devilee, Ph.D.; and Cees J. Cornelisse, Ph.D. of Leiden University Medical Center, Leiden Netherlands; and Charles W. Richard, III, M.D, Ph.D., of Wyeth-Ayerst Research.

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com